Estonia - Kiestonia - Ravimiamet

bausch + lomb ireland limited - deksametasoon - silmageel - 0,985mg 1g 5g 1tk

Estonia - Kiestonia - Ravimiamet

bausch health ireland limited - tsefprosiil - õhukese polümeerikattega tablett - 500mg 10tk

Estonia - Kiestonia - Ravimiamet

bausch health ireland limited - tsetirisiin - õhukese polümeerikattega tablett - 10mg 10tk; 10mg 7tk

Umoja wa Ulaya - Kiestonia - EMA (European Medicines Agency)

mylan ireland limited - asatsitidiin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastilised ained - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.

Estonia - Kiestonia - Ravimiamet

bausch + lomb ireland limited - travoprost - silmatilgad, lahus - 40mcg 1ml 2.5ml 4tk; 40mcg 1ml 2.5ml 1tk

Estonia - Kiestonia - Ravimiamet

bausch + lomb ireland limited - timolool+latanoprost - silmatilgad, lahus - 5mg+50mcg 1ml 2.5ml 4tk; 5mg+50mcg 1ml 2.5ml 3tk; 5mg+50mcg 1ml 2.5ml 1tk

Estonia - Kiestonia - Ravimiamet

bausch + lomb ireland limited - latanoprost - silmatilgad, lahus - 50mcg 1ml 2.5ml 1tk; 50mcg 1ml 2.5ml 3tk

Estonia - Kiestonia - Ravimiamet

bausch + lomb ireland limited - aselastiin - silmatilgad, lahus üheannuselises konteineris - 0,5mg 1ml 0.6ml 60tk; 0,5mg 1ml 0.6ml 30tk; 0,5mg 1ml 0.6ml 20tk

Umoja wa Ulaya - Kiestonia - EMA (European Medicines Agency)

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastilised ained - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

Umoja wa Ulaya - Kiestonia - EMA (European Medicines Agency)

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - oftalmoloogilised vahendid - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.